文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

清髓性HLA单倍体骨髓移植中减低剂量移植后环磷酰胺的1/2期试验

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation.
PubMed 文献 · Blood Adv · 2025-01-01

单中心前瞻性1/2期试验评估清髓性HLA单倍体骨髓移植中将移植后环磷酰胺(PTCy)减至25 mg/kg/天(第+3/+4天或仅第+4天),联合西罗莫司和吗替麦考酚酯。35例患者中,中间剂量组(n=23)无II-IV级急性GVHD,2年慢性GVHD、非复发死亡和复发累积发生率分别为13%、17%和22%。探索性分析显示中间剂量较历史高清剂量组植入更快、输血更少、口腔黏膜炎更轻。

要点

  • 中间剂量PTCy(25 mg/kg/天,第+3/+4天)未观察到剂量限制性毒性III-IV级急性GVHD。
  • 中间剂量组2年无II-IV级急性GVHD,慢性GVHD、非复发死亡、复发累积发生率分别为13%、17%、22%。
  • 探索性分析中中间剂量组较高清剂量组植入和T细胞重建更快、输血更少、口腔黏膜炎更轻。

核心结论

  • 中间剂量PTCy有效,且较高清剂量PTCy表现出明显的临床获益。
  • 在更广泛应用前,需要进一步研究确认这些发现,并确定不同供者/移植物类型的最佳PTCy剂量。

研究设计与样本

  • 单中心前瞻性1/2期试验,纳入35例接受清髓性HLA单倍体骨髓移植的患者。
  • GVHD预防方案为PTCy联合西罗莫司和吗替麦考酚酯,PTCy减至25 mg/kg/天于第+3/+4天或仅第+4天给药。
  • 35例患者中89%为少数族裔,46%为高危/极高危疾病,中位合并症评分为3。
  • 试验注册号为NCT03983850。

主要发现

  • 两种减量PTCy剂量水平后均未观察到剂量限制性毒性III-IV级急性GVHD。
  • 中间剂量PTCy(25 mg/kg/天,第+3/+4天;n=23)组无II-IV级急性GVHD发生。
  • 中间剂量组2年需全身免疫抑制的慢性GVHD、非复发死亡和复发累积发生率分别为13%、17%和22%。
  • 中间剂量组2年总生存、无病生存和无GVHD/无复发生存分别为61%、61%和52%。
  • 与高清剂量PTCy(n=5)的探索性分析中,中间剂量组植入和T细胞重建显著更快、输血更少、口腔黏膜炎更轻、BK病毒相关膀胱炎/尿道炎严重程度更低。

关键数值与推荐

  • 高清剂量PTCy为50 mg/kg/天,第+3/+4天给药。
  • 中间剂量PTCy为25 mg/kg/天,第+3/+4天给药(n=23,2期剂量)。
  • 探索性分析中高清剂量PTCy组n=5,非方案规定对照组。

临床怎么用

  • 作者认为中间剂量PTCy有效且较高清剂量PTCy有明显临床获益。
  • 作者指出在更广泛应用前需进一步研究确认这些发现并确定不同供者/移植物类型的最佳PTCy剂量。

局限性

  • 单中心研究。
  • 探索性分析中高清剂量PTCy对照仅5例。
  • 作者指出在更广泛应用前需进一步研究确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-dose posttransplantation cyclophosphamide (HD-PTCy), given at 50 mg/kg/day on days +3/+4, is a standard-of-care graft-versus-host disease (GVHD) prophylaxis for allogeneic hematopoietic cell transplantation (HCT). Our murine MHC-haploidentical HCT studies suggested intermediate-dose PTCy produces superior GVHD control compared with HD-PTCy and PTCy is maximally effective on day +4. We conducted a single-institutional prospective phase 1/2 trial to reduce PTCy dosing to 25 mg/kg/day on days +3/+4 or on day +4 only for myeloablative HLA-haploidentical bone marrow HCT using PTCy, sirolimus, and mycophenolate mofetil. Among 35 patients, 89% were ethnic/racial minorities, 46% had high/very-high-risk disease, and median comorbidity score was 3. The phase 1 dose-limiting-toxicity, grade III-IV acute GVHD, was not observed after either reduced-PTCy dose level. PTCy 25 mg/kg/day on days +3/+4 (intermediate-dose (ID)-PTCy; n = 23), the phase 2 dose, resulted in no grade II-IV acute GVHD; 2-year cumulative incidences of chronic GVHD requiring systemic immunosuppression, nonrelapse mortality, and relapse were 13%, 17%, and 22%, and 2-year overall survival, disease-free survival, and GVHD-free/relapse-free survival were 61%, 61%, and 52%. In exploratory analysis compared with HD-PTCy (n = 5), ID-PTCy resulted in significantly faster engraftment and T-cell reconstitution, fewer transfusions, less mucositis, and reduced severity of BK-virus-associated cystitis/urethritis; area-under-the-curve exposure of 4-hydroxycyclophosphamide (4HCY), a key cyclophosphamide metabolite, correlated with these outcomes but not with chronic GVHD occurrence. Ideal-body-weight-based PTCy dosing best approximated 4HCY exposure. ID-PTCy is effective and has apparent clinical benefits compared with HD-PTCy. Before broader implementation, further studies are needed to confirm these findings and define optimal PTCy dosing across various donor/graft types. This trial was registered at www.clinicaltrials.gov as #NCT03983850.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hyder MA, Dimitrova D, Sabina R, et al. Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation. Blood Adv. 2025. PMID: 39908565. doi:10.1182/bloodadvances.2024014879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。